See related research by Sakr *et al.*, <http://ccforum.com/content/14/3/R92> and related letter by Sakr and Reinhardt, <http://ccforum.com/content/14/4/431>

Dr Sakr and colleagues \[[@B1]\] report a single centre cohort study evaluating the relationship between anaemia, blood transfusions and mortality in patients admitted to a surgical ICU. The authors report some findings that are not new or surprising, namely that anaemia is associated with adverse patient outcomes. However, when they performed multivariate analyses with adjustment for potential confounders to the blood transfusion/patient outcomes relationship they found that transfusions were associated with lower patient mortality, especially among older sicker patients. At face value this contradicts the majority of previous cohort studies \[[@B2]\] and the only large randomised trial of different transfusion triggers in critically ill patients (the Canadian Critical Care Trials Group\'s \'Transfusion requirements in critical care\' (TRICC) trial) \[[@B3]\]. The authors\' findings raise a number of questions, including: does this association indicate cause and effect\'? Are the findings of the TRICC trial generalisable to intensive care patients today? And, perhaps most importantly, should we use blood more liberally in critically ill patients than the TRICC trial and our current guidelines suggest?

Does this association indicate \'cause and effect\'?
====================================================

Although it is possible to perform complex statistical adjustments for potential confounders in cohort studies to try to clarify the true relationship between a variable or intervention of interest and an outcome, this is notoriously problematic, especially in relation to blood transfusions \[[@B4]\]. Adjustments can be made for measured factors, but there is always the possibility of residual confounding from \'unknowns\', which is more likely in complex heterogeneous populations. ICU populations are highly heterogeneous at multiple levels, including pre-illness co-morbidity, diagnosis requiring admission, early illness severity, and subsequent complications, to name a few. Dr Sakr and colleagues included adjustment for some factors but, as they acknowledge, it is very likely there were many \'unknowns\' that were potentially relevant. Bias by indication is very likely in this sort of analysis whereby factors affecting a clinical decision (blood transfusion in this case) cannot be adequately captured or adjusted for, thereby introducing an imbalance. Dr Sakr and colleagues used propensity analysis in an attempt to overcome this problem, which attempts to produce matched pairs from observational data to simulate a \'virtual\' randomised trial. The limitations of this approach have been previously discussed in detail in relation to another cohort study involving some of these authors \[[@B5],[@B6]\]. Although the chance of erroneous associations is probably reduced, the problem remains that the patients being matched may differ in unmeasured ways. This might be more likely in a single centre study, such as the one performed by Dr Sakr and colleagues, where transfusion decision-making was presumably more consistent. The mean hemoglobin transfusion trigger was 8.2 g/dL and in 30% of cases it was \>9 g/dL, so this ICU was significantly more liberal than the restrictive arm of the TRICC trial \[[@B3]\]. Another issue is that there was no information about the indications for transfusion, especially bleeding, which could have created imbalance between the matched pairs. In short, we cannot be sure of causality between blood transfusions and better outcomes, but the study does stimulate us to look again at the TRICC trial and its relevance today.

Are the findings of the TRICC trial generalisable to intensive care patients today?
===================================================================================

The TRICC trial found that mortality was higher in younger patients (aged \<55 years) and those with APACHE II scores \<20 when blood was used liberally \[[@B3]\]. Treatment effects were similar for older patients and those with APACHE II scores ≥ 20, and in subgroup analyses no strong signals favouring either group were found in relation to duration of mechanical ventilation \[[@B7]\], or trauma diagnosis \[[@B8]\]. Patients with ischemic heart disease as a baseline comorbidity had a trend towards better outcome with more liberal blood use \[[@B9]\] and a later analysis highlighted the potential interaction between ischemic heart disease and the hemoglobin level maintained in intensive care, which could have been underestimated in the original trial report \[[@B10]\]. All of these subgroup analyses were underpowered, and even the full trial was much smaller than intended (the intended sample size was 1,620; achieved was 838). Another relevant factor was that clinicians declined to enrol 29% of eligible patients. These issues raise the possibility that different treatment effects might exist for patients with ischemic heart disease, and among older and/or sicker patients, especially those with evidence of inadequate oxygen delivery or delayed weaning from mechanical ventilation. These uncertainties are acknowledged in recent guidelines and systematic reviews \[[@B11],[@B12]\], and it is perhaps not surprising that surveys indicate continued variation in clinical practice \[[@B11],[@B13]\]. The other key uncertainty relates to the impact of prestorage leucodepletion, which was not used during the TRICC trial, but is now undertaken routinely in most developed countries. This additional processing step was associated with small (1% absolute risk reduction) but significant ICU mortality reduction in Canada, and may be particularly important with prolonged red cell storage \[[@B14],[@B15]\].

Should we use blood more liberally in critically ill patients than the TRICC trial and our current guidelines suggest?
======================================================================================================================

The answer to this question for younger, less severely unwell patients is surely NO. For other patients we need to continue to use clinical judgement, but the evidence is still most consistent with a target haemoglobin concentration of \<9 g/dL, especially given the potential risks of blood transfusions and uncertain effectiveness of stored red cells \[[@B11],[@B15]\]. Given our recent experiences of therapeutic strategies with early promise, but for which later trials showed conflicting safety data either overall (for example, tight glycaemic control) or in patient subgroups (for example, activated protein C), it is surely time for a \'new TRICC\'. Only well designed randomised trials will improve our confidence in making transfusion decisions. Unfortunately, studies such as the one performed by Dr Sakr and colleagues simply add to our uncertainty.
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